- Optimization of 5-arylidene barbiturates as potent, selective, reversible LSD1 inhibitors for the treatment of acute promyelocytic leukemia
-
Histone lysine specific demethylase 1 (LSD1) is overexpressed in diverse hematologic disorders and recognized as a promising target for blood medicines. In this study, molecular docking-based virtual screening united with bioevaluation was utilized to identify novel skeleton of 5-arylidene barbiturate as small-molecule inhibitors of LSD1. Among the synthesized derivatives, 12a exhibited reversible and potent inhibition (IC50 = 0.41 μM) and high selectivity over the MAO-A and MAO-B. Notably, 12a strongly induced differentiation effect on acute promyelocytic leukemia NB4 cell line and distinctly escalated the methylation level on histone 3 lysine 4 (H3K4). Our findings indicate that 5-arylidene barbiturate may represent a new skeleton of LSD1 inhibitors and 12a deserve as a promising agent for the further research.
- Xu, Siyuan,Zhou, Chen,Liu, Rongfeng,Zhu, Qihua,Xu, Yungen,Lan, Fei,Zha, Xiaoming
-
p. 4871 - 4880
(2018/09/22)
-
- DRUG WITH HEPATOPROTECTIVE ACTIVITY
-
The invention relates to pharmacology and can be used for treating liver diseases of various etiologies, inter alia, in combination with other preparations. Claimed is a drug with hepatoprotective activity comprised of 3-(4-bromophenyl)-6,6-dihydroxy-5-hydroxyiminohexahydro-2,4-pyrimidinedione and salts thereof of general formula (I), where X is selected from the group: H, Na, K, or from the group of hydroxyalkylammonia derivatives of general formula (II), where R1, R2 are selected from the group: H, CH3, CH2CH3, CH2CH2OH; R3 is selected from the group: H, CH2OH; and n=1, 2; the drug can be prepared in the form of tablets or capsules for enteral administration; or in the form of a liquid or lyophilized substance for parenteral administration; or in the form of rectal suppositories; or in the form of capsules or tablets, or sweets for sucking; and may additionally contain the hepatoprotector Heptral; or the hepatoprotector Essentiale; or the hepatoprotector ursodeoxycholic acid. This increases the effectiveness of a drug with hepatoprotective activity.
- -
-
-
- Barbiturate compound, preparing method and application thereof
-
The invention belongs to the field of medicinal chemistry, and discloses a barbiturate compound, a preparing method and application thereof. Specifically, the invention relates to the compound as shown in formula I, and a medicinal usage thereof as a selective LSD1 reversible inhibitor, particular to the application in preparing of antitumor medicine. A test shows that the compound in formula I can efficiently reversibly inhibit LSD1 activity, and has a weak inhibition action for homologous proteins MAO-A and MAO-B, can intensively induce differentiation of leukemia cell NB4 and obviously enhance the methylation level of primers H3K4me1 and H3K4me2 of the LSD1.
- -
-
-
- Chemical modification of plant alkaloids. 2. Reaction of cotarnine with barbituric acid derivatives and structure of 5-dihydrocotarnylbarbituric acids
-
The reaction of barbituric acid and its N-substituted derivatives and 2-thio analogs with cotarnine forms 5-(4-methoxy-6-methyl-5,6,7,8-tetrahydro-2H-1,3-methylenedioxy-[4,5-g]isoquinolinyl-1)barbituric acids, a new class of zwitter-ions, the structure of which was studied by 1H and 13C NMR spectroscopy and mass spectrometry. The prepared compounds exist in solution as stable intermolecular associates and have a complicated H-bonded structure.
- Krasnov,Kartsev,Yurova
-
p. 543 - 550
(2007/10/03)
-